Download MendeleyOptimization of Novel Quinazolines as Potent Aurora Kinase Inhibitors for Triple-Negative Breast Cancer Treatment.
Long, L., Zhang, B., Peng, W., Pan, Y., Zhai, H., Cheng, B., Tu, Z., Long, Z., Zhou, H., Liu, Q., Lu, G.(2025) J Med Chem 68: 18197-18215
- PubMed: 40852972
- DOI: https://doi.org/10.1021/acs.jmedchem.5c00107
- Primary Citation of Related Structures:
5ZAN - PubMed Abstract:
This work describes the discovery of a new series of Aurora kinase inhibitors based on quinazoline skeleton derived from ENMD-2076 , as well as the first X-ray cocrystal structure complexes of vinyl-quinazoline 9h with Aurora A. Replacing pyrimidine with quinazoline improved anticancer activity and facilitated cocrystal formation. Compounds 9a and 9h showed excellent Aurora A kinase inhibition, with IC 50 values of 6.0 and 2.8 nM, respectively. 9h demonstrated superior activity against TNBC MDA-MB-231 cells with an IC 50 value of 48 nM and achieved 59% tumor growth inhibition in xenograft models, vs ENMD-2076 's 33% with no observable toxicity. Mechanistic studies using immunoblotting, immunofluorescence staining, and flow cytometry showed that 9h outperforms ENMD-2076 in inhibiting Aurora A kinase activation, preventing spindle formation, arresting the cell cycle, and inducing cell apoptosis. Thus, 9h has the potential for further optimization and is a promising anticancer drug candidate.
- State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, P. R. China.
Organizational Affiliation:
